Amicus

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

Retrieved on: 
Friday, October 27, 2023
Amicus Therapeutics, Therapy, Amicus, PIN, Online shopping

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m.

Key Points: 
  • PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m.
  • ET to discuss financial results for the third quarter ended September 30, 2023.
  • Participants and investors interested in accessing the call by phone will need to register using the online registration form .
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease

Retrieved on: 
Thursday, September 28, 2023
Pharmacy, Glycogen, Glycogen storage disease, Miglustat, Amicus, Glycogen storage disease type II, Cell, Skeletal muscle, Muscle weakness, ELK, GAA, ERT, Infant, Patient, Cipaglucosidase alfa, Amicus Therapeutics, Enzyme replacement therapy, Disease, Pharmaceutical industry

ELK GROVE VILLAGE, Ill., Sept. 28, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a two-component treatment approved for certain patients with late-onset Pompe disease.

Key Points: 
  • ELK GROVE VILLAGE, Ill., Sept. 28, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a two-component treatment approved for certain patients with late-onset Pompe disease.
  • Please see full Prescribing Information, including BOXED WARNING, for POMBILITI and full Prescribing Information for OPFOLDA , also available at amicusrx.com .
  • Pompe disease is an inherited lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase.
  • We are pleased to partner with Amicus to bring Pombiliti and Opfolda to patients suffering from this devastating disease.

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

Retrieved on: 
Thursday, September 21, 2023
GMP, Hoffman, Amgen, Senior, Partner, Bayer, MBA, Georgetown University, Chemistry, Adenosine, Patient, Blue jay, Leukemia, Columbia University, Business development, BS, Cancer and Leukemia Group B, Infection, Leukemia & Lymphoma Society, MS, Corporation, Apple tree, Five-prime cap, Liver, NNRTI, Technology transfer, Roche, Business, Gilead Sciences, Amicus, Providence College, CMO, AbbVie, SAN, A2A, Amicus Therapeutics, Therapy, HBV, Catalant, SQZ, Model Business Corporation Act, HIV, Chiron Corporation, Hepatology, Oppenheimer, CMC, NDA, Hepatitis C, IND World's Fair Line, HCV, Management, Pharmaceutical industry, Genentech, ImmunityBio COVID-19 vaccine, Biotechnology, Searle

He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

Key Points: 
  • He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu.
  • “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies.
  • Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities.

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, August 8, 2023
Fabry, Loss, Table, Civil service commission, CER, CER1, Amicus, GAAP, PIN, Retirement, Acquisition, Patient, Cipaglucosidase alfa, Growth, CFO, Depreciation, Diagnosis, Commercial, Amicus Therapeutics, Therapy, European Commission, Pharmaceutical industry, Video game, Cryptocurrency, EU, Migalastat

The Company continues to expect regulatory approvals of AT-GAA in both the U.S. and U.K. in the third quarter of 2023.

Key Points: 
  • The Company continues to expect regulatory approvals of AT-GAA in both the U.S. and U.K. in the third quarter of 2023.
  • Total revenue in the second quarter 2023 was $94.5 million, a year-over-year increase of 17% from total revenue of $80.7 million in the second quarter 2022.
  • Total GAAP operating expenses of $104.2 million for the second quarter 2023 decreased as compared to $133.1 million for the second quarter 2022.
  • ET to discuss the second quarter 2023 financial results and corporate updates.

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

Retrieved on: 
Monday, July 31, 2023
PIN, Amicus Therapeutics, Amicus, Therapy, Online shopping

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m.

Key Points: 
  • PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m.
  • ET to discuss financial results for the second quarter ended June 30, 2023.
  • Participants and investors interested in accessing the call by phone will need to register using the online registration form .
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, May 10, 2023
Fabry, Loss, Table, Civil service commission, CER, CER1, European Directive on Traditional Herbal Medicinal Products, Amicus, Glycogen storage disease type II, GAAP, Committee, PIN, EAMS, Acquisition, Patient, Physician, Cipaglucosidase alfa, European, Growth, WuXi Biologics, Depreciation, Diagnosis, Committee for Medicinal Products for Human Use, Orange Book, Amicus Therapeutics, FDA, Therapy, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Wuxi, CHMP, Pharmaceutical industry, Bank, Video game, Cryptocurrency, EU, Migalastat

In the U.K., the regulatory submission process was initiated in December 2022, with final approval expected in the third quarter of 2023.

Key Points: 
  • In the U.K., the regulatory submission process was initiated in December 2022, with final approval expected in the third quarter of 2023.
  • Total GAAP operating expenses of $117.0 million for the first quarter 2023 decreased as compared to $146.5 million for the first quarter 2022.
  • ET to discuss the first quarter 2023 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

Retrieved on: 
Monday, May 1, 2023
PIN, Amicus Therapeutics, Amicus, Therapy, Online shopping

PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m.

Key Points: 
  • PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m.
  • ET to discuss financial results for the first quarter ended March 31, 2023.
  • Participants and investors interested in accessing the call by phone will need to register using the online registration form .
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol

Retrieved on: 
Sunday, April 23, 2023
Pharmaceutical, Medical Supplies, Surgery, Oncology, Health, Diabetes, Medical Devices, Hospitals, CE, TPE, Fresenius (company), ECP, Cutaneous T-cell lymphoma, CTCL, Amicus, Medical Device Regulation Act, Kabi, Sale, Medical device regulation, MNC, Patient, Collection, Physician, Skin, Medical device, EU

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

Key Points: 
  • Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
  • The Amicus Blue System with online ECP was launched in Europe in 2019 with double-needle venous access only.
  • “We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access.
  • This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs,” said Christian Hauer, President Fresenius Kabi MedTech.

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, March 1, 2023
CHMP, Glycogen storage disease type II, Safety, Depreciation, Therapy, Amicus, Diagnosis, Amicus Therapeutics, Growth, Committee, CER1, Committee for Medicinal Products for Human Use, GAAP, Acquisition, EAMS, FDA, Patient, Fabry disease, CER, Table, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Loss, PIN, European Directive on Traditional Herbal Medicinal Products, Food, Physician, Pharmaceutical industry, Cryptocurrency, Bank, Migalastat, Fabry, EU

The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022, with final approval expected in the third quarter of 2023.

Key Points: 
  • The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022, with final approval expected in the third quarter of 2023.
  • Amicus Therapeutics will host a conference call and audio webcast today, March 1, 2023 at 8:30 a.m.
  • ET to discuss the full-year 2022 financial results and corporate updates.
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

Retrieved on: 
Tuesday, February 14, 2023
PIN, Therapy, Amicus, Amicus Therapeutics, Online shopping

PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m.

Key Points: 
  • PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m.
  • ET to discuss financial results for the full-year ended December 31, 2022.
  • Participants and investors interested in accessing the call by phone will need to register using the online registration form .
  • A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .